- Home
- AMTB vs ATXS Comparison
AMTB vs ATXS Comparison
Compare AMTB & ATXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMTB
- ATXS
- Stock Information
- Founded
- AMTB 1979
- ATXS 2008
- Country
- AMTB United States
- ATXS United States
- Employees
- AMTB N/A
- ATXS N/A
- Industry
- AMTB Major Banks
- ATXS Biotechnology: Pharmaceutical Preparations
- Sector
- AMTB Finance
- ATXS Health Care
- Exchange
- AMTB Nasdaq
- ATXS Nasdaq
- Market Cap
- AMTB 792.0M
- ATXS 676.1M
- IPO Year
- AMTB N/A
- ATXS 2015
- Fundamental
- Price
- AMTB $16.99
- ATXS $12.51
- Analyst Decision
- AMTB Buy
- ATXS Buy
- Analyst Count
- AMTB 4
- ATXS 7
- Target Price
- AMTB $22.25
- ATXS $30.00
- AVG Volume (30 Days)
- AMTB 292.5K
- ATXS 4.1M
- Earning Date
- AMTB 10-28-2025
- ATXS 11-12-2025
- Dividend Yield
- AMTB 2.15%
- ATXS N/A
- EPS Growth
- AMTB N/A
- ATXS N/A
- EPS
- AMTB 1.58
- ATXS N/A
- Revenue
- AMTB $388,004,000.00
- ATXS N/A
- Revenue This Year
- AMTB $62.48
- ATXS N/A
- Revenue Next Year
- AMTB $6.58
- ATXS N/A
- P/E Ratio
- AMTB $10.56
- ATXS N/A
- Revenue Growth
- AMTB 51.78
- ATXS N/A
- 52 Week Low
- AMTB $15.62
- ATXS $3.56
- 52 Week High
- AMTB $26.24
- ATXS $12.65
- Technical
- Relative Strength Index (RSI)
- AMTB 31.52
- ATXS 82.95
- Support Level
- AMTB $15.62
- ATXS $12.40
- Resistance Level
- AMTB $17.68
- ATXS $12.65
- Average True Range (ATR)
- AMTB 0.70
- ATXS 0.24
- MACD
- AMTB -0.11
- ATXS 0.05
- Stochastic Oscillator
- AMTB 31.92
- ATXS 97.92
About AMTB Amerant Bancorp Inc.
Amerant Bancorp Inc is a bank holding company. Through its bank, it provides individuals and businesses deposit, credit, investment, wealth management, and fiduciary services, both in the United States and to select international customers. The bank also provides banking services through traditional channels, such as banking centers and ATMs, as well as via secure websites, mobile devices and telephones.
About ATXS Astria Therapeutics Inc.
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.